Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 8/20 | 0.50 |
| ▸ | CDK2 | P24941 | 4/20 | 0.50 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28835066 | 0.85 | CDC7 (0.47) | CDC7CDK2MAP3K14ALDH1A1KDM4E | |
| SCHEMBL506374 | 0.77 | CYP2A6 (0.49) | CDC7CDK2MAP3K14ALDH1A1KDM4E | |
| SCHEMBL27924593 | 0.77 | CDC7 (0.48) | CDC7CDK2MAP3K14ALDH1A1KDM4E | |
| SCHEMBL30089263 | 0.77 | CYP2A6 (0.49) | CDC7CDK2MAP3K14ALDH1A1KDM4E | |
| SCHEMBL20340238 | 0.75 | CDC7 (0.46) | CDC7CDK2MAP3K14ALDH1A1KDM4E | |
| SCHEMBL28417198 | 0.74 | NOTUM (0.53) | CDC7CDK2MAP3K14ALDH1A1KDM4E | |
| SCHEMBL20656047 | 0.73 | ALDH1A1 (0.50) | CDC7CDK2MAP3K14ALDH1A1KDM4E | |
| SCHEMBL20655577 | 0.73 | CDC7 (0.44) | CDC7CDK2MAP3K14ALDH1A1KDM4E | |
| SCHEMBL18585228 | 0.73 | CDC7 (0.44) | CDC7CDK2MAP3K14ALDH1A1KDM4E | |
| SCHEMBL30940222 | 0.72 | CDC7 (0.41) | CDC7CDK2MAP3K14ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306638-A1 | BENZISOXAZOLE PIPERIDINYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE DERIVATIVES AND THEIR USE | NHWA PHARMA. CORPORATION (CN) | 2011-12-15 | — | — | US | disclosed |
| CN-101759693-B | Benzo-isoxazol piperidine derivative and application in preparing analgesic and sedative medicaments | JIANGSU ENHUA PHARMACEUTICAL CO LTD | 2011-09-14 | — | — | CN | disclosed |
| CN-101759693-A | Benzo-isoxazol piperidine derivative and application in preparing analgesic and sedative medicaments | NHWA PHARMACEUTICAL GROUP CO L | 2010-06-30 | — | — | CN | disclosed |
| EP-1827427-B1 | ARYLOXYETHYLAMINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARM BV (NL) | 2008-07-23 | — | — | EP | disclosed |
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-03-29 | — | — | US | disclosed |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
| US-5488113-A | Process for the preparation of 1-hydroxyindole compounds | EASTMAN CHEMICAL COMPANY (US) | 1996-01-30 | — | — | US | disclosed |
| US-5434271-A | 1-hydroxyindole compounds | EASTMAN CHEMICAL COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306638-A1 | BENZISOXAZOLE PIPERIDINYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE DERIVATIVES AND THEIR USE | HTR2A, HTR2C, HTR5A | CDC7 4801/4885CDK2 2154/4885MAP3K14 2841/4885 |
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | HTR2C, HTR2A, HTR5A | CDC7 4307/4885CDK2 943/4885MAP3K14 2240/4885 |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | HTR2C, HTR2A, HTR5A | CDC7 4307/4885CDK2 943/4885MAP3K14 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.